Cost-Effectiveness Analysis

By R. Chisin. Journal of Nuclear Medicine, 2009

1,000 citations recorded by the source corpus.

Subfields: Economics and Econometrics, General Health Professions, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/426386bf6af8e608808ad71d98191feee10a05ef

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Economics and Econometrics

1. Leonard N. Masse
2. W. S. Barnett

In General Health Professions

1. Leonard N. Masse
2. W. S. Barnett

In Radiology, Nuclear Medicine and Imaging

1. Leonard N. Masse
2. W. S. Barnett

Citations in the corpus

• Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. (2016, background): “Even if duration of protection is 20 years for a 2dose series and lifelong for a 3-dose series, additional benefits of a 3-dose series would be relatively small, and a 2-dose series would be more cost-effective (14).”
• Comparative benefit-cost analysis of the Abecedarian program and its policy implications (2007, methodology): “Benefit–cost analysis of the Abecedarian program followed standard procedures (Levin & McEwan, 2001) and is methodologically comparable with benefit–cost analyses of the Perry Preschool program (Barnett, 1996; Nores, Barnett, Belfield, & Schweinhart, 2005).”